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reached statistical significance. The included studies differed in their design and population 81 definitions, with a considerable heterogeneity limiting the significance of the meta-analysis. 82 Moreover, these studies had some specific methodological limitations, such as the absence of 83 a power calculation and exposures were often recorded at the time of diagnosis or treatment, 84 rather than considering the exposure history prior to diagnosis. The latter raises the 85 possibility of a bias due to cancer symptoms (e.g. weight loss, new onset diabetes) or lifestyle 86 modifications such as changes in smoking behaviour and alcohol consumption. 87 It appears that there is overlap in risk factors, such as smoking and alcohol, for the 88 occurrence of PNENs and pancreatic adenocarcinoma, however, a number of other factors 89 that have been associated with the occurrence of pancreatic cancer have not, to our 90 knowledge, been investigated for PNENs. For example, the use of medications such as aspirin, 91 and the association with allergy and atopy that have been reported to be protective against 92 pancreatic adenocarcinoma occurrence (Gomez-Rubio, et al. 2015; Streicher, et al. 2014).  93 For these reasons, we conducted a multi-center European study aimed at assessing the 94 association between a large number of potential risk or protective factors for the 95 development of sporadic PNENs. 96 
 97 
Materials and Methods 98  99 
Study Design and population 100 A collaborative multicentre hospital based case-control study was conducted in six European 101 countries: Italy, Norway, Sweden, Slovenia, United Kingdom and Germany as part of the 102 










Cases were classified according with the European Neuroendocrine Tumor Society 128 (ENETs) and the 2010 World Health Organization classifications (Falconi et al. 2016; Rindi G ; 129 Solcia E 2002). 130 Eligible controls were either individuals seen in the participating hospitals’ outpatient 131 clinic for a non-specific, non-organic gastrointestinal disorder (bloating, aspecyfic dyspeptic 132 symptoms, eructation) or visitors attending the same network of referring hospitals, matched 133 by country, sex and age (+/- 5 years). Visitors and hospital outpatients’ clinic belonged to the 134 same catchment area of cases. Specific exclusion criteria for controls were: 1) the presence of 135 any genetic syndrome associated with the occurrence of PNENs; 2) a history of active cancer 136 (diagnosed within 5 years); 3) any biological relation of a participating PNEN case in this 137 study; 4) a history of any chronic inflammatory condition (e.g. chronic obstructive pulmonary 138 disease, liver cirrhosis, inflammatory bowel disease, end stage kidney disease); 5) undergoing 139 evaluation of a possible familial cancer syndrome. Controls were included in the same country 140 and interviewed within 6 months of the inclusion of the matched corresponding case. 141  142 





A daily intake of at least 12.5 g of alcohol, equivalent to one glass of wine, one pint of 152 beer or one shot of hard liquor, for at least one year, was considered the cut-off to be a regular 153 ever alcohol drinker. Because of possible different drinking habits within different European 154 countries, the weekly alcohol amount was also sub-analyzed according to low (1-7 weekly 155 units assumption), medium (8-14 weekly units), medium-high (14-20 weekly units) and 156 
heavy alcohol consumption (≥21 weekly units). Coffee drinking was also recorded as ever 157 drinking (at least one cup per day) or heavy coffee drinking (>5 cups per day). 158 Height and weight were recorded from which body mass index (BMI) (kg/m2) was 159 calculated. A history of chronic pancreatitis, acute pancreatitis, peptic ulcer disease, biliary 160 stones and previous surgery were specifically recorded. Additionally, a diagnosis of diabetes 161 was documented and subdivided for type and onset. For cases, recent onset diabetes was 162 defined as that which was diagnosed in the 12 months prior to the PNEN diagnosis, and for 163 controls a diagnosis of diabetes 12 months prior to the date of recruitment was required. 164 Sensitivity analysis were also performed for different intervals of the onset of diabetes, 165 (respectively inferior to 1 year, between 1 and 3 years, between 3 and 5 years and above 5 166 years). Another sensitivity analysis was also conducted considering incident/prevalent cases 167 and hospitals controls/visitors controls compared to respective cases.  168 As atopy and allergy have been associated with a reduced risk of pancreatic cancer 169 (Gomez-Rubio et al. 2015), cases and controls were interrogated about a history of allergy, 170 with specific enquiry for eczema, hay fever and asthma. The use of aspirin, proton pump 171 inhibitors, metformin and insulin were recorded. Subjects were interrogated about 1st and 2nd 172 degree family history of cancer, and the total number of siblings and children was recorded. 173  174 





An a priori power calculation was performed. We estimated sample size based on the 176 differences reported in the frequencies of exposure in cases and controls according to a 177 previous study (Capurso et al. 2009), and considering a ratio 1:3, with a statistical power 178 equal to 80% and an alpha error equal to 0.05. 179 According to Capurso and colleagues (Capurso et al. 2009) the reported prevalence in cases 180 and controls was respectively 53% vs. 32% for 1st degree family history of cancer, 10% vs. 2% 181 for diabetes and 14% vs. 3% for heavy alcohol consumption. Therefore, the sample size’s 182 estimate of cases and controls, to show true differences whether existing, were respectively 183 64 cases and 191 controls for 1st degree family history of cancer, 117 cases and 350 controls 184 for diabetes, 85 cases and 253 controls for heavy alcohol consumption. 185 We therefore estimated that a total of 200 cases and 600 controls across participating 186 centers, to be an adequate sample size to reveal differences in the prevalence of most risk 187 factors analyzed among cases and controls, where these exist. 188 Characteristics of cases and controls were compared by chi-square test for categorical 189 
variables or Student’s t test for continuous variables. Significant variables were analyzed by 190 logistic regression analysis adjusted for sex, age and enrolment center. A multivariable logistic 191 regression analysis, adjusted for sex, age and enrolment center was also performed with an 192 enter selection procedure for statistically significant risk factors. A dedicated statistical 193 software package (MedCald Mariakerke, Belgium) was used for data analysis. The 95 % 194 confidence interval (CI 95) was calculated where possible. All p-values were two-sided and a 195 p<0.05 was considered statistically significant . 196 
 197 
RESULTS 198 





A total of 201 cases and 603 sex and age matched controls were enrolled among the six 200 centers (Italy, Norway, Sweden, United Kingdom, Slovenia and Germany) as shown in table 1. 201 The mean age was 59.6 years in cases (CI 57.7-61.4) and 59.5 years in controls (CI 58.4-202 60.55), and 51% of cases and controls were male.  203 Amongst the 201 PNEN cases, 154 (76.6%) had a non-functioning tumor. Of the 47 204 functioning PNENs, 26 (55.3%) had an insulinoma, 9 (19.1%) a gastrinoma, 7 (14.9%) a 205 glucagonoma and 5 (10.6%) other functioning tumors. The majority were G1 (44.8%) or G2 206 (43.3%) PNENs, and were equally distributed among different disease stages (Table 1). Of the 207 201 PNEN cases, 80 (38%) cases were incident and 121 (62%) prevalent. Of the 603 controls, 208 422 (70%) were hospital outpatients controls and 181 (30%) visitors.  209 
 210 
Risk factors for the occurrence of PNEN 211 
 212 
Family history of cancer 213 The proportion of subjects who had a 1st degree family history of cancer was similar in cases 214 and in controls (respectively 51.1% vs. 45.3% p=0.17), while 2nd degree family history was 215 slightly more prevalent in cases ( 36.8% vs. 30.2% p=0.09). A 1st degree family history of 216 specific cancer sites was also not significantly different (Table 2). No cases or controls 217 reported a family history of neuro-endocrine tumor (NET). At multiple regression analysis 2nd 218 degree family history of any cancer was, however associated with an increased risk of PNEN 219 
(see Table 2 and 3). 220 
 221 





Mean BMI was not significantly different amongst cases and controls (26.8 kg/m2 (CI 26.0-223 27.5) and 26.4 kg/m2 (CI 26.4-26.8), p=0.10. Similarly, whilst the overall prevalence of obesity 224 was more frequent in cases than controls (25.5% vs. 18.2%) this was not significant (p=0.44).  225 At regression analysis after adjustment for matching variables, there remained no significant 226 association with obesity (OR 1.36, 95% CI 0.88-2.08, p=0.15) (Table 3). 227  228 
Cigarette smoking, alcohol intake and coffee drinking 229 The proportion of smokers (55.5% vs. 53.5%, p=0.59), heavy smokers (25.5% vs. 24.0%, 230 p=0.59), alcohol drinkers (75.6% vs. 70.8%, p=0.33), heavy alcohol drinkers (3.4% vs. 4.2%, 231 p=0.33), coffee drinkers (84.8% vs. 87.8%, p=0.24) and heavy coffee drinkers (18.8% vs. 232 19.2%, p=0.24) did not significantly differ between cases and controls (Table 2). 233 
 234 





years no statistically significant difference was found between cases and controls 248 (respectively 10.7% vs 7.4%, p=0.16) (Table 2). We also performed a separate analysis for 249 
“late onset diabetes” using as controls either only the 422 hospital controls or only the 181 250 visitors controls. In the first case the OR resulted to be 2.52 (95%CI 1.08-5.86; p=0.03), while 251 in the second one the OR was 1.7 (95%CI 0.95-3; p=0.07), most likely due to the lower 252 number of controls reducing the power of the analysis. 253 Neither the use of metformin (7.3% vs. 5.1%, p=0.3), nor insulin (4.1% vs. 1.6%, p=0.1), or 254 their association together (5.2% vs 3.4%, p=0.4) were statistically different between cases 255 and controls.   256 
Past medical history 257 With regards to past medical history, the prevalence of acute pancreatitis (3.5% vs. 2.4%, 258 p=0.60), peptic ulcer disease (12.3% vs. 10.6%, p=0.59), cholecystectomy (9.0% vs. 8.5%, 259 p=0.92) and gastrectomy (1.0% vs. 0.7%, p=0.99) were similar in cases and controls. None of 260 the participants reported a medical history of chronic pancreatitis (Table 2). A higher 261 proportion of cases reported a history of gallstone disease than controls (19.2% vs. 13.3%) 262 but this did not reach the significance threshold (p=0.06). After adjustment for age, sex and 263 enrolment center at multivariable analysis, this latter association remained borderline 264 significant (OR 1.52, 95% CI 0.95-2.44, p=0.08) (Table 3). 265 
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A history of allergies was not different in cases and in controls (28.9% vs. 25.0%, p=0.32). 272 Specifically, neither asthma (12.1% vs. 8.6%, p=0.19), eczema (11.1% vs. 7.6%, p=0.17) nor 273 hay fever (15.6% vs. 14.5%, p=0.79) were more prevalent in PNEN patients than in controls 274 (Table 2). 275  276 















cancer-related symptom, we performed a further sensitivity analysis, investigating several 342 different intervals of time between the onset of diabetes and the diagnosis of cancer.  Non 343 recent onset diabetes was confirmed to be increasingly consistent with the occurrence of 344 PNEN for intervals superior to 1 year and up to 5 years. For intervals of onset of diabetes 345 superior to 5 years this association was not anymore statistically significant. This might be 346 interpreted on the base of a lack of power of the study when considering small subgroups or,  347 alternatively, it could be biologically explained by the trophic influence that diabetes plays on 348 cancer. On the other hand one should also take into account that PNEN display a slower 349 growing rate compared to PDAC and therefore it might justify a major latency of occurrence of 350 symptom diabetes. 351 As the potential role of anti-diabetic drugs (metformin and insulin) in influencing pancreatic 352 carcinogenesis has been reported (De Souza, et al. 2016), we also specifically investigated the 353 role of such drugs in our multi-national cohort. Although the prevalent use insulin alone was 354 more frequent among cases than in controls (4.1% vs 1.6%), this difference was not significant 355 as the study was underpowered to assess it. 356 Another noteworthy finding of the present study was the increased proportion of 357 gallstone disease amongst PNEN cases compared to controls. However, this did not reach 358 statistical significance and we therefore cannot conclude that this was anything more than a 359 chance observation. The apparent proportional increase amongst cases, however, may reflect 360 the universal use of abdominal imaging in those diagnosed with PNEN, as compared to occult 361 gallstones in controls. It may be that our study was underpowered to detect a true association 362 between PNEN and biliary calculi, as the latter have been found to be associated with 363 















control population. We opted for a mixed control group that we believed to represent the 417 same population as the case group, as living in the same catchment area of the corresponding 418 cases, to limit possible bias that could have been specific of either hospital controls or visitors. 419 
Interestingly, “late onset diabetes” seemed to be associated with an increased risk of PNEN 420 with both kind of controls used in separate analyses. 421 In conclusion, the findings of this large multicentre case-control study suggest that 422 non-recent onset diabetes was associated with an increased risk of PNENs occurrence. Our 423 results do not support the view of a strict similarity with factors affecting the risk of 424 pancreatic adenocarcinoma. 425 
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